Drugs / Margetuximab
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04398108 | Aug 2020 → Apr 2021 | HER2 positive breast carcinoma | Zai Lab (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03219268 | Aug 2017 → Feb 2023 | cervical cancer, cholangiocarcinoma, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm +4 | MacroGenics | Completed | No outcome recorded |
| Phase 1 | NCT01148849 | Jul 2010 → Jun 2022 | breast cancer, gastric cancer | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02689284 | Jan 2016 → Jan 2021 | esophageal cancer, gastric cancer | MacroGenics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05227131 | May 2022 → Oct 2024 | HER2 positive breast carcinoma | MedSIR | Withdrawn | No outcome recorded |
| Phase 2 | NCT04425018 | Jul 2020 → Oct 2024 overdue | HER2 positive breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262804 | Jan 2020 → Sep 2021 | breast carcinoma | Zai Lab (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01828021 | Mar 2013 → Dec 2016 | breast cancer | MacroGenics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04082364 | Sep 2019 → Jan 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | MacroGenics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02492711 | Aug 2015 → Aug 2021 | HER2 positive breast carcinoma, metastatic neoplasm | MacroGenics | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03133988 Background | — | HER2 positive breast carcinoma | TerSera Therapeutics LLC | Approved for marketing | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | margetuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04082364 ↗ |
| Known as | Margenza | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364649 ↗ |
| Known as | Margetuximab cmkb | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364649 ↗ |
| Known as | MGAH22 | “First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.” PMID 28119295 ↗ Apr 2017 |
| Action | Inhibit | “anti-HER2 monoclonal antibody” PMID 32653053 ↗ Jul 2020 |
| Modality | Monoclonal antibody | “First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.” PMID 28119295 ↗ Apr 2017 |
| Route | Intravenous | “treated with margetuximab by intravenous infusion” PMID 28119295 ↗ Apr 2017 |
| Target | ERBB2 | “Margetuximab is an anti-HER2 antibody” PMID 28119295 ↗ Apr 2017 |